Milledge has served as the company’s chairman of the board since April 2009. Former CEO Martin Dieck will assume the role of president and COO.

Nfocus claims that it is developing treatment for brain aneurysms called LUNA, designed to be a direct replacement to detachable coils, which provide physicians with a single-deployment, easy-to-use embolization device.

Nfocus director and InCube Labs CEO Mir Imran said that he was pleased about Milledge’s 34 year history with J&J along with Martin’s 18 year neurovasc and the company’s approach to treat aneurysms has the potential to become the new standard of care and is expected to offer benefits over coils.

“With Milledge and Martin at the helm, I’m confident that Nfocus is poised for clinical and commercial success in this greatly important area of aneurysm therapy,” Imran said.

Milledge said that Nfocus’ LUNA technology has the potential to be a breakthrough in treating aneurysms and this is a critical time as they continue to expand clinical trials in Europe.